Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: CS 670; DW-330; DW-330SR; Pelubi; Pelubiprofen sustained release; RS 2131

Latest Information Update: 28 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sankyo
  • Developer Daewon Pharmaceutical; Sankyo
  • Class Analgesics; Antipyretics; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Back pain; Osteoarthritis
  • Phase III Fever
  • No development reported Musculoskeletal pain; Rheumatoid arthritis
  • Discontinued Rheumatic disorders

Most Recent Events

  • 28 Mar 2018 No recent reports of development identified for phase-I development in Musculoskeletal-pain(In volunteers) in South Korea (PO, Controlled release)
  • 07 Mar 2016 Pelubiprofen is still in phase III trials in Fever in South Korea (PO)
  • 01 Mar 2016 Daewon completes a phase-III clinical trial in Fever in South Korea (PO) (NCT01779271)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top